There were significant improvements in the primary and secondary endpoints (PVR, 6MWD, NT-proBNP, functional class, mean pulmonary artery pressure, right atrial pressure), with no differences in cardiac output and pulmonary arterial wedge pressure; proving long-term safety and efficacy of sotatercept in PAH. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.